From academics and biotechs of every size to large pharma, we democratize access to foundational, pre-competitive biologics discovery technologies and services to enable drug discovery across six biologic modalities. When you partner with Alloy, you can:
Access our ever-growing stable of services and cutting-edge technology platforms to help you discover the best therapeutic antibodies against yo
ur targets. Unlock the therapeutic potential of T cell receptor (TCR) modalities through our fully integrated Keyway™ TCR Discovery service offering. Reach intracellular disease targets at the nucleic acid level with our novel AntiClastic™ ASO Format, which enhances the drug-like properties of antisense . Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with labs in Cambridge, U.K.; Basel, CH; San Francisco, CA; and Athens, GA. We reinvest 100% of our revenue into innovation and access to continuously develop new groundbreaking platforms and protocols to make our collaborators more successful. Better Leads. Better Biologics. Get your best therapeutic candidate to market faster: https://www.alloytx.com/
